Home > Resources > Whitepapers > Whitepaper: Discriminating copy number variation from heterogeneous samples using the S3™ Cell Sorter and the QX200™ Droplet Digital™ PCR System

Whitepaper: Discriminating copy number variation from heterogeneous samples using the S3™ Cell Sorter and the QX200™ Droplet Digital™ PCR System

November 1, 2016

Many biological samples are composed of mixtures of physiologically different cell types. These include stem cell cultures, tumor samples, and blood.Understanding the genetic makeup of a subpopulation within these samples may provide valuable clues about the characteristics of the sample and, by extension, the organism. For example, identifying and characterizing rapidly growing subpopulations within a tumor may reveal the metastatic potential of the cancer.

Spotlight

Envy Medical, Inc.

Envy Medical emerged in the field of dermatology and medical aesthetics in 1999 as a medical device and skin care leader with a strong culture in innovation and a solid reputation for clinically-backed, scientifically-proven products.

OTHER WHITEPAPERS

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | December 6, 2022

BioPhorum’s mission is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all.

The colors of life: an interdisciplinary artist-in-residence project to research fungal pigments as a gateway

whitePaper | January 10, 2022

Biological pigmentation is one of the most intriguing traits of many fungi. It holds signifcance to scientists, as a sign of biochemical metabolism and organism-environment interaction, and to artists, as the source of natural colors that capture the beauty of the microbial world.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

DIGITAL BIOTECH IS MISSION-CRITICAL TO MODERNA

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.